Table 1 Literature review

From: Modelling prognostic factors in advanced pancreatic cancer

Type (number) of studies

Number of patients per study

Prognostic factors reported (frequency of reporting)

U or MV analysis

Randomised controlled trial (n=4)3–6

207–322

Surgical

Metastases

(3)

4 MV

   

Tumour location

(1)

 
  

Clinical

Performance status

(3)

 
   

Treatment

(1)

 
  

Laboratory

Alkaline phosphatase

(1)

 

Consecutive series >500 patients (n=3)7–9

782–2380

Surgical

Metastases

(1)

2 MV

   

Stage of disease

(1)

1 U

   

Operation

(1)

 
  

Clinical

Performance status

(1)

 
   

Diabetes

(1)

 
   

Pain

(1)

 
   

Appetite/weight

(1)

 
   

Jaundice

(1)

 
   

Treatment

(1)

 
  

Laboratory

Albumin

(1)

 
  

Demographic

Age

(1)

 
   

Specialist centre

(1)

 

Consecutive series 100–500 patients (n=14)10–23

102–450

Surgical

Metastases

(4)

13 MV

   

Stage of disease

(2)

1 U

   

Tumour location

(1)

 
   

Operation

(2)

 
   

Tumour size

(1)

 
   

Duodenal invasion

(1)

 
   

Peridissemination

(1)

 
   

Ascites

(1)

 
  

Clinical

Performance status

(2)

 
   

Diabetes

(1)

 
   

Pain

(1)

 
   

Appetite/weight

(3)

 
   

Symptom onset

(1)

 
   

Treatment

(2)

 
  

Laboratory

CA242

(2)

 
   

CA19-9

(2)

 
   

Leukocytes

(1)

 
   

Gamma GT

(1)

 
   

Albumin

(1)

 
   

LDH

(1)

 
   

CRP

(3)

 
   

Iron

(1)

 
  

Demographic

Age

(1)

 

Consecutive series

28–95

Surgical

Metastases

(1)

8 MV

<100 patients (n=15)24–38

  

Stage of disease

(1)

7 U

   

Grade of disease

(1)

 
   

Nodal status

(1)

 
   

Operation

(1)

 
   

Tumour size

(2)

 
   

Fibrosis

(1)

 
  

Clinical

Performance status Inflammation

(4)

 
   

Appetite/weight

(1)

 
   

Treatment

(1)

 
  

Laboratory

CA19-9

(1)

 
   

VEGF

(7)

 
   

CEA

(1)

 
   

Phase angle BIA

(1)

 
   

SCA

(1)

 
    

(1)

 
  1. MV=multivariate; U=univariate.